サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1793640

神経疾患診断の世界市場

Neurological Disorder Diagnostics

出版日
ページ情報
英文 367 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.79円
神経疾患診断の世界市場
出版日: 2025年08月19日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 367 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

神経疾患診断の世界市場は2030年までに米国で136億米ドルに達する見込み

2024年に99億米ドルと推定される神経疾患診断の世界市場は、2024年から2030年にかけてCAGR 5.6%で成長し、2030年には136億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである画像診断は、CAGR 4.6%を記録し、分析期間終了時には86億米ドルに達すると予測されます。In-Vitro Diagnostics分野の成長率は、分析期間中CAGR 7.3%と推定されます。

米国市場は27億米ドル、中国はCAGR 8.6％で成長すると予測

米国の神経疾患診断市場は、2024年に27億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR 8.6％を引きずる形で、2030年までに27億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.8％と5.4％と予測されています。欧州では、ドイツがCAGR 3.6%で成長すると予測されています。

世界の神経疾患診断市場- 主要動向と促進要因のまとめ

複雑化する疾患は診断アプローチをどのように変えているか？

神経疾患には、アルツハイマー病、パーキンソン病、多発性硬化症、てんかん、脳卒中など幅広い疾患が含まれます。これらの疾患は重複した症状を呈することが多く、正確な診断をますます複雑にしています。神経変性の理解が進むにつれ、診断法は早期段階での同定と個別化評価へとシフトしています。CTスキャンやMRIのような伝統的な診断ツールは現在、PETイメージング、脳脊髄液分析、電気生理学的モニタリングなどの先端技術によって補完されつつあります。

分子診断法、特にアミロイド斑やタウ蛋白を検出するバイオマーカーを用いた診断法は、臨床症状が発現するかなり前に神経変性疾患を特定する上で重要性を増しています。より早期かつ正確な検出を目指すこの動きは、プロテオミクス、ゲノミクス、画像インフォマティクスの進歩によって支えられてきました。また、デジタル・プラットフォームとAIベースのアナリティクスを統合することで、症状があいまいであったり、時間の経過とともに変化したりする場合でも、臨床医が異なる神経疾患をより効率的に区別できるようになっています。

診断精度の向上にテクノロジーが果たす役割とは？

技術の統合により、神経学的診断の精度と範囲は大幅に向上しました。高解像度の画像診断ツールにより、脳の形態、血管の異常、機能障害に関する詳細な洞察が得られるようになりました。拡散テンソル画像や機能的MRIのようなMRI技術は、特にてんかんや外傷性脳損傷の評価において、脳活動のマッピングにますます使用されるようになっています。一方、EEGやMEG技術は、てんかん、睡眠障害、脳症におけるリアルタイムの神経電気モニタリングに不可欠です。

もう一つの重要な動向は、外来や在宅での利便性を提供する、非侵襲的でポータブルな診断装置の台頭です。ウェアラブル神経モニタリングシステムやモバイルEEGソリューションは、脳活動を継続的に追跡するのに役立ち、医師は標準的な臨床検査では現れないような断続的な異常を特定できます。クラウド接続と遠隔診断により、特にサービスが行き届いていない地域や農村部において、専門的な評価へのアクセスがさらに広がっています。

なぜ個別化診断が臨床上の優先事項となりつつあるのか？

個別化医療が重視されるようになったことで、神経学的診断の解釈や適用方法が変わりつつあります。神経疾患の進行や治療に対する反応に著しい不均一性が見られることから、診断法は個人のリスクプロファイルに合わせて調整されるようになってきています。これには、遺伝性神経変性疾患（ハンチントン病や家族性アルツハイマー病など）を検出するための遺伝子スクリーニングや、認知機能検査パターンや画像データに基づいて疾患の経過を評価するための機械学習アルゴリズムの活用が含まれます。

脳スキャン、神経心理学的評価、体液バイオマーカー、遺伝子検査などのデータを組み合わせたマルチモーダル診断は、臨床試験や研究プログラムへの導入が進んでいます。これらのアプローチは疾患の早期発見に役立つだけでなく、より良い治療法の選択、反応モニタリング、予後予測をサポートします。製薬企業も診断薬開発企業と協力して、神経学に特化した医薬品開発プログラムにコンパニオン診断薬を組み込もうとしています。

神経疾患診断市場の成長はいくつかの要因によってもたらされます。

人口の高齢化とライフスタイルに関連したリスク因子の増加により、神経変性疾患や神経血管障害の世界の負担が増加しているため、正確で早期段階の診断に対する強い需要が生まれています。画像技術、バイオマーカー探索、デジタル診断プラットフォームの進歩により、評価の信頼性とアクセス性が高まっています。AIとデータ分析の神経診断システムへの統合は、特に複雑な症例における診断精度をさらに向上させています。神経科学研究への投資増加や専門診断センターの利用可能性の拡大も市場拡大を支えています。在宅神経学的評価ツールの開発は、早期介入戦略に対する規制当局の支援とともに、ヘルスケアシステム全体での診断製品開発の技術革新を引き続き後押ししています。

セグメント

製品（画像診断、体外診断）;疾患（遺伝性神経疾患、免疫性神経疾患、腫瘍随伴性症候群、腫瘍随伴性神経障害）;エンドユーザー（病院・専門クリニック、診断センター、外来手術センターエンドユーザー）

調査対象企業の例

  • Abbott Laboratories
  • Advanced Brain Monitoring, Inc.
  • Biogen Inc.
  • Bio-Rad Laboratories, Inc.
  • Canon Medical Systems Corporation
  • Elekta AB
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Holdings Corporation
  • GE HealthCare
  • Hologic, Inc.
  • IXICO plc
  • Lifelines Neuro Company LLC
  • Masimo Corporation
  • Medtronic plc
  • NeuroPace, Inc.
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Philips Healthcare（Koninklijke Philips）
  • QIAGEN N.V.
  • Siemens Healthineers AG

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37491

Global Neurological Disorder Diagnostics Market to Reach US$13.6 Billion by 2030

The global market for Neurological Disorder Diagnostics estimated at US$9.9 Billion in the year 2024, is expected to reach US$13.6 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Imaging Diagnostics, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$8.6 Billion by the end of the analysis period. Growth in the In-Vitro Diagnostics segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 8.6% CAGR

The Neurological Disorder Diagnostics market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 8.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Neurological Disorder Diagnostics Market - Key Trends & Drivers Summarized

How Is Evolving Disease Complexity Reshaping Diagnostic Approaches?

Neurological disorders encompass a wide range of conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, and stroke. These disorders often present with overlapping symptoms, making accurate diagnosis increasingly complex. As the understanding of neurodegeneration advances, diagnostics are shifting toward early-stage identification and personalized evaluation. Traditional diagnostic tools like CT scans and MRIs are now being complemented by advanced techniques including PET imaging, cerebrospinal fluid analysis, and electrophysiological monitoring.

Molecular diagnostics, particularly those using biomarkers for detecting amyloid plaques or tau proteins, are gaining importance in identifying neurodegenerative conditions well before the onset of clinical symptoms. This push for earlier and more precise detection has been supported by advances in proteomics, genomics, and imaging informatics. Integration of digital platforms and AI-based analytics is also enabling clinicians to distinguish between different neurological conditions more efficiently, even when symptoms are ambiguous or evolve over time.

What Role Does Technology Play in Expanding Diagnostic Accuracy?

Technological integration has significantly enhanced the accuracy and scope of neurological diagnostics. High-resolution imaging tools now provide detailed insights into brain morphology, vascular anomalies, and functional disturbances. MRI techniques like diffusion tensor imaging and functional MRI are increasingly used for mapping brain activity, particularly in epilepsy and traumatic brain injury assessments. Meanwhile, EEG and MEG technologies continue to be vital for real-time neuroelectrical monitoring in epilepsy, sleep disorders, and encephalopathies.

Another key trend is the rise of non-invasive and portable diagnostic devices, which offer convenience in outpatient or home-based settings. Wearable neuro-monitoring systems and mobile EEG solutions are helping track brain activity continuously, allowing physicians to identify intermittent abnormalities that may not appear during standard clinical tests. Cloud connectivity and remote diagnostics are further widening access to specialized evaluations, particularly in underserved or rural areas.

Why Are Personalized Diagnostics Becoming a Clinical Priority?

Growing emphasis on personalized medicine is transforming how neurological diagnostics are interpreted and applied. With neurological disorders showing significant heterogeneity in progression and response to treatment, diagnostics are now being tailored to individual risk profiles. This includes using genetic screening to detect hereditary neurodegenerative disorders, such as Huntington’s disease or familial Alzheimer’s, as well as leveraging machine learning algorithms to assess disease trajectory based on cognitive test patterns and imaging data.

Multimodal diagnostics, which combine data from brain scans, neuropsychological assessments, fluid biomarkers, and genetic tests, are being increasingly deployed in clinical trials and research programs. These approaches not only help in early disease detection but also support better treatment selection, response monitoring, and prognosis prediction. Pharmaceutical companies are also collaborating with diagnostics developers to embed companion diagnostics into neurology-focused drug development programs.

Growth in the neurological disorder diagnostics market is driven by several factors.

Increasing global burden of neurodegenerative and neurovascular disorders, driven by aging populations and rising lifestyle-related risk factors, has created strong demand for accurate and early-stage diagnostics. Advancements in imaging technology, biomarker discovery, and digital diagnostic platforms have made evaluations more reliable and accessible. Integration of AI and data analytics into neurodiagnostic systems is further improving diagnostic precision, especially in complex cases. Rising investment in neuroscience research and the growing availability of specialized diagnostic centers are also supporting market expansion. Adoption of home-based neurological assessment tools, along with regulatory support for early intervention strategies, continues to encourage innovation in diagnostic product development across healthcare systems.

SCOPE OF STUDY:

The report analyzes the Neurological Disorder Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Imaging Diagnostics, In-Vitro Diagnostics); Disorder (Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder, Paraproteinemic Neuropathies Disorder); End-Use (Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use, Ambulatory Surgery Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott Laboratories
  • Advanced Brain Monitoring, Inc.
  • Biogen Inc.
  • Bio-Rad Laboratories, Inc.
  • Canon Medical Systems Corporation
  • Elekta AB
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Holdings Corporation
  • GE HealthCare
  • Hologic, Inc.
  • IXICO plc
  • Lifelines Neuro Company LLC
  • Masimo Corporation
  • Medtronic plc
  • NeuroPace, Inc.
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Philips Healthcare (Koninklijke Philips)
  • QIAGEN N.V.
  • Siemens Healthineers AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Neurological Disorder Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Neurological Disorders Drives Demand for Early Diagnostic Solutions
    • Advancements in Neuroimaging Technologies Spur Growth in Accurate and Non-Invasive Diagnostics
    • Increased Adoption of AI and Machine Learning Enhances Diagnostic Accuracy and Workflow Efficiency
    • Expansion of Point-of-Care Neurological Testing Devices Strengthens Market Accessibility
    • Integration of Genomic and Molecular Biomarkers Propels Personalized Neurology Diagnostics
    • Aging Population and Age-Associated Cognitive Decline Expand Addressable Market Opportunity
    • Growing Focus on Pre-Symptomatic Detection Generates Demand for Predictive Neurological Tools
    • Widening Application of EEG and MEG Systems Drives Clinical Adoption Across Hospitals and Clinics
    • Rise in Concussions and Sports-Related Brain Injuries Throws the Spotlight on Portable Diagnostic Tools
    • Increased Use of Companion Diagnostics in Neurology Strengthens Business Case for Targeted Testing
    • Digital Neurology Platforms and Remote Monitoring Tools Create New Diagnostic Pathways
    • Widespread Use of Wearables in Cognitive Health Monitoring Drives Market Penetration
    • Emerging Role of Liquid Biopsy in CNS Disorders Expands Future Diagnostic Capabilities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Neurological Disorder Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Neurological Disorder Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Neurological Disorder Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Imaging Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Imaging Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Imaging Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for In-Vitro Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for In-Vitro Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for In-Vitro Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Genetic Neurological Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Genetic Neurological Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Genetic Neurological Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immunological Neurological Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Immunological Neurological Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Immunological Neurological Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Paraneoplastic Syndrome Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Paraneoplastic Syndrome Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Paraneoplastic Syndrome Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Paraproteinemic Neuropathies Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Paraproteinemic Neuropathies Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Paraproteinemic Neuropathies Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals & Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospitals & Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Neurological Disorder Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Neurological Disorder Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Neurological Disorder Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Neurological Disorder Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Neurological Disorder Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Neurological Disorder Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Neurological Disorder Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Neurological Disorder Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION